Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Fiche publication
Date publication
septembre 2022
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain, Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Meynard L, Dinart D, Delaunay B, Fléchon A, Saldana C, Lefort F, Gravis G, Thiery-Vuillemin A, Cancel M, Coquan E, Ladoire S, Maillet D, Rolland F, Boughalem E, Martin S, Laramas M, Crouzet L, Abbar B, Falkowski S, Pouessel D, Roubaud G
Lien Pubmed
Résumé
Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challenge after ICI, compared with second-line chemotherapy without previous ICI in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
Mots clés
Chemotherapy, Immune checkpoint inhibitor, Urothelial carcinoma
Référence
Eur J Cancer. 2022 09 8;175:43-53